It is possible combining AHN augmentation, e.g., stimulating BDNF signaling, with IL-1 antagonism that reduces hyper-IL-1-signaling induced suppression of AHN could be an effective therapeutic strategy for the treatment of PTSD. The gene discussed is IL1B; the disease is post-traumatic stress disorder.